Related Experiment Video
Updated: Jun 19, 2026

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
Published on: August 19, 2021
Sentinel lymphadenectomy in breast cancer: an update on the NCCN clinical practice guidelines
1Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. banderso@u.washington.edu
Abstract:
Sentinel lymphadenectomy is an acceptable surgical technique for axillary staging among patients with clinically node-negative stage I or stage II breast cancer with primary invasive tumors measuring less than 5 cm. Patient selection and mapping team experience are critical factors for mapping success and accuracy. In the 2002 NCCN guidelines, exclusion criteria for sentinel node mapping include tumor multicentricity, the use of preoperative (neoadjuvant) chemotherapy or hormonal therapy, and a large excision (more than 6 cm) of the primary tumor performed before mapping. Future studies will clarify whether these exclusions are overly restrictive. Until then, the NCCN guidelines present a conservative perspective on sentinel lymphadenectomy, confirming that complete level I or level II axillary lymph node dissection remains the gold standard for breast cancer axillary staging.
